Norgine launches Mugard for oral mucositis in Spain
Mugard is a medical device for the prevention and management of the signs and symptoms of oral mucositis caused by chemotherapy and radiation therapy.
Norgine has launched Mugard, a medical device for the prevention and management of the signs and symptoms of oral mucositis caused by chemotherapy and radiation therapy in Spain. Approximately 177,000 cases of oral mucositis occur each year in Spain.
Mugard is a mucoadhesive oral rinse proven to prevent and manage the lesions and symptoms of oral mucositis by adhering to the mucosal surface of the mouth and forming a soothing, protective layer. Approximately 20-40% of patients receiving conventional chemotherapy and nearly all patients receiving head and neck radiation therapy suffer from oral mucositis. With limited effective treatment options available, Mugard has been created for patients to take prior to and during cancer treatment to relieve the signs and symptoms of oral mucositis.
Peter Martin, Chief Operating Officer, Norgine said: "We are delighted to launch Mugard in Spain as it provides cancer patients with an important treatment for oral mucositis, when we know there are limited effective treatment options available. Managing the side effects of cancer treatment is essential to keeping patients on their cancer therapy."
Norgine holds the rights to Mugard in Europe, Australia and New Zealand. Norgine anticipates further launches of Mugard in 2016 and 2017.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.